KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biocryst Pharmaceuticals (BCRX) Equity Average (2016 - 2026)

Biocryst Pharmaceuticals filings provide 15 years of Equity Average readings, the most recent being -$253.5 million for Q4 2025.

  • On a quarterly basis, Equity Average rose 46.32% to -$253.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$253.5 million, a 46.32% increase, with the full-year FY2025 number at -$297.5 million, up 36.11% from a year prior.
  • Equity Average hit -$253.5 million in Q4 2025 for Biocryst Pharmaceuticals, up from -$404.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of -$47.1 million in Q1 2021 to a low of -$475.9 million in Q2 2024.
  • Median Equity Average over the past 5 years was -$335.0 million (2023), compared with a mean of -$308.0 million.
  • Biggest five-year swings in Equity Average: tumbled 1867.17% in 2021 and later skyrocketed 46.32% in 2025.
  • Biocryst Pharmaceuticals' Equity Average stood at -$127.0 million in 2021, then tumbled by 111.49% to -$268.6 million in 2022, then tumbled by 61.29% to -$433.3 million in 2023, then fell by 9.0% to -$472.2 million in 2024, then skyrocketed by 46.32% to -$253.5 million in 2025.
  • The last three reported values for Equity Average were -$253.5 million (Q4 2025), -$404.7 million (Q3 2025), and -$436.8 million (Q2 2025) per Business Quant data.